{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T07:34:30Z","timestamp":1775374470350,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astex Pharmaceuticals Inc"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boerhinger Ingelheim"},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008422","name":"Endocyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incyte"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PharmaMar"},{"name":"TESARO"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ogc.2018.09.005","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T08:12:15Z","timestamp":1548403935000},"page":"67-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ovarian Cancer"],"prefix":"10.1016","volume":"46","author":[{"given":"Rebecca Ann","family":"Previs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogc.2018.09.005_bib1","unstructured":"Cancer facts & figures 2018: special section: ovarian cancer. 2018. Available at: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2018.html."},{"issue":"10","key":"10.1016\/j.ogc.2018.09.005_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9990","key":"10.1016\/j.ogc.2018.09.005_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ogc.2018.09.005_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ogc.2018.09.005_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ogc.2018.09.005_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical practice guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib7","article-title":"Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602","volume":"36","author":"Onda","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","article-title":"A\u00a0multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer","volume":"134","author":"Suidan","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2018.09.005_bib9","doi-asserted-by":"crossref","first-page":"462.e1","DOI":"10.1016\/j.ajog.2013.07.016","article-title":"A\u00a0multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer","volume":"209","author":"Fagotti","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2018.09.005_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ygyno.2004.11.031","article-title":"Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study","volume":"96","author":"Fagotti","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ogc.2018.09.005_bib12","doi-asserted-by":"crossref","first-page":"642.e1-6","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2015.03.049","article-title":"Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care","volume":"137","author":"Gomez-Hidalgo","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ogc.2018.09.005_bib14","unstructured":"National Comprehensive Cancer Network (US). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. version 2.2018. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf."},{"issue":"15_suppl","key":"10.1016\/j.ogc.2018.09.005_bib15","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/JCO.2017.35.15_suppl.5500","article-title":"LION: Lymphadenectomy In Ovarian Neoplasms\u2014A prospective randomized AGO study group led gynecologic cancer intergroup trial","volume":"35","author":"Harter","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib16","article-title":"LION-PAW: Lymphadenectomy In Ovarian Neoplasm\u2013Pleasure Ability of Women\u2014Prospective substudy of the randomized multicenter LION study","volume":"36","author":"Hasenburg","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ogc.2018.09.005_bib17","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Bois","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib18","volume":"36","author":"Robert","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ogc.2018.09.005_bib19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ogc.2018.09.005_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3\u00a0weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ogc.2018.09.005_bib21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl_5","key":"10.1016\/j.ogc.2018.09.005_bib22","first-page":"v605","volume":"28","author":"Clamp","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib23","article-title":"Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: a multi-center, randomized, open-label, phase III trial","volume":"36","author":"Li","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2018.09.005_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/IGC.0b013e3181cafb47","article-title":"Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study","volume":"20","author":"Takakura","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"24","key":"10.1016\/j.ogc.2018.09.005_bib25","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","article-title":"Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial","volume":"34","author":"Sugiyama","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2018.09.005_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ogc.2018.09.005_bib27","unstructured":"Walker JL, BM, DiSilvestro PA, et\u00a0al. A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): a GOG\/NRG trial (GOG 252). Society of Gynecologic Oncology Annual Meeting Late-breaking abstract 6 Presented San Diego, CA, March 21, 2016. 2016."},{"issue":"6","key":"10.1016\/j.ogc.2018.09.005_bib28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/AOG.0000000000001436","article-title":"Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer","volume":"127","author":"Wright","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib30","article-title":"A\u00a0phase I dose-escalation of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin for the frontline treatment of advanced ovarian cancer","volume":"36","author":"Leslie","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ogc.2018.09.005_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"issue":"29","key":"10.1016\/j.ogc.2018.09.005_bib33","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study","volume":"35","author":"Pignata","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.ogc.2018.09.005_bib34","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ogc.2018.09.005_bib35","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ogc.2018.09.005_bib36","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/cncr.29995","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy","volume":"122","author":"Matulonis","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ogc.2018.09.005_bib37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ogc.2018.09.005_bib38","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ogc.2018.09.005_bib39","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10106","key":"10.1016\/j.ogc.2018.09.005_bib40","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib41","article-title":"Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study","volume":"36","author":"Aghajanian","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ogc.2018.09.005_bib43","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl_6","key":"10.1016\/j.ogc.2018.09.005_bib44","first-page":"856O","article-title":"Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)","volume":"27","author":"Kristeleit","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2018.09.005_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib46","article-title":"QUADRA: a phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received \u22653 prior chemotherapy regimens","volume":"36","author":"Kathleen","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ogc.2018.09.005_bib48","unstructured":"Administration USFD. FDA approves bevacizumab in combination with chemotherapy for ovarian cancer. Available at: https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm610664.htm."},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib49","article-title":"Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: a NRG oncology\/Gynecologic Oncology Group (GOG) study","volume":"36","author":"Burger","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.ogc.2018.09.005_bib50","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ogc.2018.09.005_bib51","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ogc.2018.09.005_bib52","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2018.09.005_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2014.02.003","article-title":"Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer","volume":"133","author":"Aghajanian","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2018.09.005_bib54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ogc.2018.09.005_bib55","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib56","article-title":"Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17","volume":"36","author":"Pignata","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"33","key":"10.1016\/j.ogc.2018.09.005_bib57","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"33","key":"10.1016\/j.ogc.2018.09.005_bib58","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.ogc.2018.09.005_bib59","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10023","key":"10.1016\/j.ogc.2018.09.005_bib60","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib61","article-title":"A\u00a0phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca)","volume":"36","author":"Liu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ogc.2018.09.005_bib62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib63","article-title":"Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: a single-arm, open-label, phase 2 study","volume":"36","author":"Lan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib64","volume":"36","author":"Vergote","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib65","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T\u00a0cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ogc.2018.09.005_bib67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.ogc.2018.09.005_bib68","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ogc.2018.09.005_bib69","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.ogc.2018.09.005_bib70","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ogc.2018.09.005_bib71","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ogc.2018.09.005_bib72","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"34","key":"10.1016\/j.ogc.2018.09.005_bib73","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ogc.2018.09.005_bib74","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1200\/jco.2015.33.15_suppl.5509","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial","volume":"33","author":"Disis","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ogc.2018.09.005_bib75","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib76","article-title":"TOPACIO\/Keynote-162 (NCT02657889): a phase 1\/2 study of niraparib\u00a0+ pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014Results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.ogc.2018.09.005_bib77","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2217\/fon-2018-0070","article-title":"Avelumab (anti-PD-L1) in platinum-resistant\/refractory ovarian cancer: JAVELIN ovarian 200 phase III study design","volume":"14","author":"Pujade-Lauraine","year":"2018","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.ogc.2018.09.005_bib78","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2017.03.509","article-title":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","volume":"145","author":"Szender","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ogc.2018.09.005_bib79","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/2326-6066.CIR-13-0089","article-title":"Effect of Montanide and poly-ICLC adjuvant on human self\/tumor antigen-specific CD4+ T\u00a0cells in phase I overlapping long peptide vaccine trial","volume":"1","author":"Tsuji","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"10.1016\/j.ogc.2018.09.005_bib80","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.ogc.2018.09.005_bib81","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","article-title":"Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer","volume":"2","author":"Odunsi","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib82","article-title":"A\u00a0phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission","volume":"36","author":"O'Cearbhaill","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ogc.2018.09.005_bib83","article-title":"Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): interim analysis of a phase 2, open-label, randomized, multicenter trial","volume":"36","author":"Rob","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_8","key":"10.1016\/j.ogc.2018.09.005_bib84","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann Oncol"},{"issue":"38","key":"10.1016\/j.ogc.2018.09.005_bib85","doi-asserted-by":"crossref","first-page":"64607","DOI":"10.18632\/oncotarget.19929","article-title":"CAR-T cell therapy in ovarian cancer: from the bench to the bedside","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ogc.2018.09.005_bib86","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A\u00a0phase I clinical trial of adoptive T\u00a0cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"June 20 Supplement","key":"10.1016\/j.ogc.2018.09.005_bib87","first-page":"18S","article-title":"Neoadjuvant chemotherapy in advanced epithelial ovarian oancer (EOC): A phase III randomized study","volume":"24","author":"Kumar","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"10.1016\/j.ogc.2018.09.005_bib88","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854518300937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854518300937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:19:04Z","timestamp":1760177944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854518300937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0889854518300937"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2018.09.005","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Obstetrics and Gynecology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogc.2018.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}